First AD

Second AD

Ofatumumab vs Teriflunomide: ASCLEPIOS I/II RMS Trials

OLKIOS: Looking at Ofatumumab’s Continued Efficacy

OPTIMUM: Ponesimod Superiority in MRI-based Outcomes in RRMS

Rationale for Selected Dosing Regimen of Evobrutinib in Phase 3 Studies 

Takeaways From ACTRIMS-ECTRIMS 2020 Meeting

Phase 3 ASCLEPIOS I/II Open-Label Extension Study: Ofatumumab vs Teriflunomide 

OLKIOS Phase 3b Trial: Pivotal Endpoints and Potential Significance

OPTIMUM Phase 3 Trial: Ponesimod’s Cardiac Safety Data

Ozanimod Compared to Teriflunomide Utilizing Statistical Matching

Key Takeaways from the 8th ACTRIMS-ECTRIMS 2020 Meeting

Ofatumumab vs Teriflunomide: Phase 3 ASCLEPIOS I/II Open-Label Extension Study

Chief Endpoints and Potential Significance: Phase 3b OLIKOS Trial

CLARITY Extension Trial: Disability Improvement With Cladribine

COVID-19 in MS Global Data-Sharing Initiative Anti-CD20 Therapy Results 

Impact of Results From the COVID-19 in MS Global Data-Sharing Initiative 

News Network

Multiple Sclerosis

 multiple sclerosis (MS) clinical focus page offers information, podcasts, videos, and news about the latest study and clinical trial findings, FDA actions, clinical guideline updates, and expert interviews related to the care and management of patients with MS, including relapsing MS and progressive MS, as well as related disorders such as neuromyelitis optica spectrum disorder.

Conferences

News

Videos

Americas Committee for Treatment and Research in Multiple Sclerosis

Experts in multiple sclerosis review top data presented at the 8th joint ACTRIMS-ECTRIMS meeting. 

Rapid Readout: Expert Perspectives on Multiple Sclerosis - Data from the 8th Joint ACTRIMS-ECTRIMS Meeting 2020